• Tetrahydromagnolol (SKU C5552): Reliable CB2 Agonist for Ass

  2026-05-28

  Tetrahydromagnolol (SKU C5552) is a highly selective peripheral CB2 receptor agonist, offering reproducible potency and workflow clarity for cell viability and GPCR signaling assays. This article explores real laboratory scenarios, guiding researchers in protocol design, data interpretation, and vendor selection. Discover how Tetrahydromagnolol streamlines cannabinoid receptor research and anti-inflammatory mechanism studies.

• Arctigenin Inhibits HCC via PI3K/AKT Pathway Modulation

  2026-05-28

  Yu et al. (2025) demonstrate that arctigenin, a natural lignan from Saussurea medusa, suppresses hepatocellular carcinoma by targeting the PI3K/AKT pathway. Integrating network pharmacology, in vitro, and in vivo work, the study provides mechanistic insight into apoptosis induction and tumor suppression, highlighting arctigenin's translational potential for liver cancer therapy.

• Adenosine Triphosphate (ATP) in Advanced Cellular Metabolism

  2026-05-27

  Adenosine triphosphate (ATP) is indispensable for probing metabolic flux and receptor signaling in experimental biology. This article details optimized protocols, troubleshooting strategies, and the latest applied insights—anchored in mitochondrial regulation—to empower rigorous cellular metabolism research using ATP from APExBIO.

• QSHXO Modulates Autophagy and Ferroptosis in MASLD Mouse Mod

  2026-05-27

  Liu et al. provide mechanistic evidence that Qushi Huoxue ointment (QSHXO) alleviates metabolic associated steatotic liver disease (MASLD) in mice by activating autophagy and inhibiting ferroptosis. This study clarifies the molecular basis for QSHXO’s hepatoprotective effects and underscores the therapeutic relevance of targeting cellular stress pathways in MASLD.

• Antiarrhythmic Drugs and KCa2 Channel Selectivity in AF Ther

  2026-05-26

  This study systematically evaluates whether established and emerging antiarrhythmic drugs, including Vernakalant Hydrochloride (RSD1235), affect small conductance calcium-activated potassium (KCa2.X) channels—a potential atrial-selective target in atrial fibrillation (AF) therapy. The findings clarify that most current AF drugs, including vernakalant, do not meaningfully inhibit KCa2.X channels at therapeutic concentrations, underscoring the need for further target-specific drug development.

• Future-Proofing Immunoassays: HyperFluor 488 and Translation

  2026-05-26

  Explore how the HyperFluor™ 488 Goat Anti-Human IgG (H+L) Antibody from APExBIO drives next-generation immunoassay performance. This thought-leadership article bridges mechanistic insight and strategic guidance, contextualizing the antibody’s advantages for translational researchers tackling evolving SARS-CoV-2 variants and beyond.

• NSC 87877: Shp2 Inhibitor Workflows for Neuroinflammation St

  2026-05-25

  NSC 87877, a potent and selective Shp2 inhibitor, empowers precise dissection of neuroinflammatory pathways and targeted modulation in both in vitro and in vivo models. With robust selectivity, reproducible solubility, and translational support from emerging stroke research, it stands out as an advanced tool for mechanistic and therapeutic studies.

• Myriocin and SPT Inhibition: Strategic Leverage in Translati

  2026-05-25

  This thought-leadership article synthesizes mechanistic insights and translational strategy for researchers investigating sphingolipid metabolism and its clinical implications. It specifically explores Myriocin’s role as a potent, selective serine palmitoyltransferase inhibitor, illuminating its impact on oncology, immunology, and cardiovascular research. By integrating pivotal findings from recent cardiac remodeling studies and advanced workflow guides, this piece positions Myriocin as a critical enabler for bridging basic science and therapeutic innovation, while distinguishing itself from standard product literature.

• JNJ-10198409: Precision Platelet-Derived Growth Factor Recep

  2026-05-24

  JNJ-10198409 sets a benchmark for selective PDGF-BB receptor inhibition, empowering angiogenesis and tumor biology researchers with nanomolar efficacy and robust workflow control. Its ATP-competitive action translates into reliable, reproducible suppression of PDGF-driven proliferation and angiogenesis, with tailored protocols for in vitro and in vivo models.

• Protease Inhibitor Cocktail (EDTA-Free, 100X in DMSO): Use G

  2026-05-23

  Protease Inhibitor Cocktail (EDTA-Free, 100X in DMSO) is designed to prevent protein degradation during extraction and sample preparation, especially when downstream applications are sensitive to divalent cations. It is not suitable for workflows requiring metalloprotease inhibition via EDTA or where DMSO is incompatible.

• Trametinib (GSK1120212): Precision MEK Inhibition in Tumor H

  2026-05-22

  Explore how Trametinib (GSK1120212) enables nuanced dissection of MEK-ERK pathway dynamics and therapeutic heterogeneity in cancer research. This article delivers advanced scientific context and practical guidance for leveraging Trametinib’s unique properties in complex, evolving tumor models.

• Acetoacetic Acid Sodium Salt: Precision Metabolic Modeling &

  2026-05-22

  Explore advanced strategies for using Acetoacetic acid sodium salt in precision energy metabolism research and diabetic ketoacidosis modeling. This article reveals unique protocol design insights and practical assay considerations for sodium 3-oxobutanoate, setting it apart from standard overviews.

• 3-Methyladenine: Optimizing Autophagy Research Workflows

  2026-05-21

  3-Methyladenine (3-MA) from APExBIO enables precise, reproducible control of autophagy for cancer and migration studies. This article delivers step-by-step protocol enhancements, troubleshooting guidance, and cross-study integration to empower experimental success.

• Thioguanine: Mechanistic Precision Driving Translational Imp

  2026-05-21

  Explore how Thioguanine (6-thioguanine) delivers targeted antitumor and antiviral action through dual inhibition of DNMT1 and HGPRT, bridging mechanistic insight and strategic translational guidance. This article moves beyond conventional product detail, synthesizing recent clinical and experimental findings to empower researchers with actionable, scenario-driven protocols and a forward-looking perspective on maximizing impact in oncology and virology.

• Cathepsin B Inhibitor CA-074: Technical Guidance for Researc

  2026-05-20

  Cathepsin B inhibitor CA-074 (SKU A1926) enables researchers to selectively block cathepsin B with nanomolar potency, supporting studies in cancer metastasis, neurotoxicity, and immune modulation. It is most applicable where reproducible, target-specific inhibition is required, but should not be used as a pan-cathepsin inhibitor or where long-term solution stability is critical.

525 records 6/35 page Previous Next First page 上5页 678910 下5页 Last page